We are live on ! Find out more
LEXXW

Lexaria Bioscience Warrant
LEXXW

Delisted

LEXXW was delisted on the 13th of January, 2026.

Back to rankings

5 hedge funds and large institutions have $125K invested in Lexaria Bioscience Warrant in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more funds holding

Funds holding: 3 → 5 (+2)

68% less capital invested

Capital invested by funds: $389K → $125K (-$264K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
5
Holders Change
+2
Holders Change %
+66.67%
% of All Funds
0.08%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$8.69K
2
UBS Group
UBS Group
Switzerland
+$129

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$7.94K
Name Holding Trade Value Shares
Change 		Change in
Stake
BFM
1
Boothbay Fund Management
New York
$57.7K – – –
SM
2
Sabby Management
Florida
$52.8K -$7.94K -22,992 -9%
CH
3
CVI Holdings
Delaware
$9.24K – – –
Citadel Advisors
4
Citadel Advisors
Florida
$5.54K +$8.69K +25,171 New
UBS Group
5
UBS Group
Switzerland
$82 +$129 +373 New

LEXXW Hedge Fund Activity: Q2 2023 in Review

5 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Lexaria Bioscience Warrant (LEXXW) for Q2 2023, worth a combined $125K — down 68% from $389K a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new LEXXW positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 1 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $8.69K. The largest seller was Sabby Management, cutting an estimated $7.94K.

  • 5 institutional investors held Lexaria Bioscience Warrant (LEXXW) as of Q2 2023, up from 3 in Q1 2023.
  • Funds reported $125K of Lexaria Bioscience Warrant stock for Q2 2023, down 68% quarter-over-quarter.
  • 2 funds opened new Lexaria Bioscience Warrant positions in Q2 2023 and 0 closed out, a net change of +2 holders.
  • The largest Lexaria Bioscience Warrant buyer in Q2 2023 was Citadel Advisors, an estimated $8.69K added.
  • The largest Lexaria Bioscience Warrant seller in Q2 2023 was Sabby Management, an estimated $7.94K sold.

Based on aggregated 13F filings for Q2 2023.